Cargando…
Rituximab
Rituximab (Rituxan(®), MabThera(®), and Genentech/Roche) is a chimeric murine/human monoclonal IgG1k antibody directed against the CD20 antigen located at the surface of normal and malignant B lymphocytes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/978-88-470-...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121599/ http://dx.doi.org/10.1007/978-88-470-5313-7_35 |
| _version_ | 1783515238132350976 |
|---|---|
| author | Tridente, Giuseppe |
| author_facet | Tridente, Giuseppe |
| author_sort | Tridente, Giuseppe |
| collection | PubMed |
| description | Rituximab (Rituxan(®), MabThera(®), and Genentech/Roche) is a chimeric murine/human monoclonal IgG1k antibody directed against the CD20 antigen located at the surface of normal and malignant B lymphocytes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/978-88-470-5313-7_35) contains supplementary material, which is available to authorized users. |
| format | Online Article Text |
| id | pubmed-7121599 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71215992020-04-06 Rituximab Tridente, Giuseppe Adverse Events with Biomedicines Article Rituximab (Rituxan(®), MabThera(®), and Genentech/Roche) is a chimeric murine/human monoclonal IgG1k antibody directed against the CD20 antigen located at the surface of normal and malignant B lymphocytes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/978-88-470-5313-7_35) contains supplementary material, which is available to authorized users. 2013-07-12 /pmc/articles/PMC7121599/ http://dx.doi.org/10.1007/978-88-470-5313-7_35 Text en © Springer-Verlag Italia 2014 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Article Tridente, Giuseppe Rituximab |
| title | Rituximab |
| title_full | Rituximab |
| title_fullStr | Rituximab |
| title_full_unstemmed | Rituximab |
| title_short | Rituximab |
| title_sort | rituximab |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121599/ http://dx.doi.org/10.1007/978-88-470-5313-7_35 |
| work_keys_str_mv | AT tridentegiuseppe rituximab |